BCR/ABL antisense oligonucleotides
Latest Information Update: 20 Jan 2017
At a glance
- Originator Lynx Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action DNA inhibitors; Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myeloid leukaemia